Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from BioNTech

US Government Calls For Additional Doses Of Pfizer/BioNTech COVID-19 Vaccine

Pfizer Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) have announced a new vaccine supply agreement with the U.S. government. Under the agreement, the U.S. government will receive 105 million doses (30 µg, 10 µg and 3 µg). This may include adult omicron-adapted COVID-19 vaccines, subject to the FDA authorization. The doses are planned to be delivered…

Benzinga

Pfizer, Moderna Analysts Respond To FDA COVID Booster Ruling: 'Revenues Will Decline'

The Food and Drug Administration’s panel of independent vaccine experts recently voted 19 to 2 to recommend a new batch of COVID-19 booster shots targeting the omicron variant this fall. The news, announced Tuesday, June 28, could have a big impact on the share prices of vaccine makers.

Benzinga

Canada needs to invest more money into science innovation to help prevent the next global crisis

Canada has lagged behind its peer nations in innovation for decades. Currently, Canada is ranked 11th out of the 16 similarly developed countries assessed. While our “C” grade is a moderate improvement over our previous “D” grade, innovation still remains a barrier to high-quality job creation and economic prosperity in…

The Conversation

From analysis to the latest developments in health,
read the most diverse news in one place.

Why Pfizer Partner BioNTech Shares Are Rising Today

BioNTech SE - ADR (NASDAQ: BNTX) shares are trading higher by 6.31% at $142.50 after the company announced its Omicron-adapted COVID-19 vaccine candidates demonstrated high immune response against the Omicron variant.

Benzinga

BioNTech Gets EMA's Priority Medicines Status For Testicular Cancer Drug

BioNTech (NASDAQ: BNTX) received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for its product candidate BNT211 in the third- or later-line treatment of testicular germ cell tumors.

Benzinga

Research behind COVID vaccines reaps close to $1 billion in royalties for Penn

PHILADELPHIA — The University of Pennsylvania has reaped extraordinary financial gain from COVID-19 vaccines — approaching $1 billion since the beginning of last year — thanks to patents on a process Penn researchers developed more than 15 years ago.

The Philadelphia Inquirer

BioNTech Whale Trades Spotted

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 14 strange trades.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Pfizer-BioNTech COVID-19 Vaccine Receives FDA Emergency Use Nod For Kids As Young As Six Months

The FDA has granted emergency use authorization (EUA) to Pfizer Inc (NYSE:PFE) and BioNTech SE's (NASDAQ:BNTX) COVID-19 Vaccine as a three 3-µg dose series for children six months through 4 years of age. Based on safety, tolerability, and immunogenicity data, the 3-µg dose was carefully selected as the preferred dose for children under five. The EUA…

Benzinga

BioNTech Whale Trades For June 10

A whale with a lot of money to spend has taken a noticeably bearish stance on BioNTech. Looking at options history for BioNTech (NASDAQ:BNTX) we detected 10 strange trades.

Benzinga

Breakthrough vaccine raises hopes of pancreatic cancer cure

Experts say vaccines could train the immune system to kill cells associated with pancreatic cancer

Wales Online

Breakthrough vaccine could help cure pancreatic cancer

Early trial results suggest personalised vaccines could stop deadly disease returning

The Independent UK

Pfizer submits COVID-19 shot for children under 5 for FDA authorization

WASHINGTON — Pfizer Inc. asked U.S. regulators to clear its COVID-19 vaccine for emergency use in children under age 5, an effort to extend protection against the virus to the country’s youngest.

Tribune News Service

Pfizer COVID shot seems protective for children under 5 in early data

Pfizer Inc. and BioNTech SE said their COVID-19 vaccine was highly effective and prompted a strong immune response in children under age 5, based on early results from a trial that is likely to pave the way for infants and toddlers to finally get immunized.

Tribune News Service

Covid vaccine: Pfizer says three doses enough to protect children under 5

Three doses of Pfizer’s Covid-19 vaccine will offer strong protection for children younger than 5, the company announced on Monday.

Evening Standard

Get all your
news in one place.

100’s of premium titles.
One news app.

Reuters

Pfizer/BioNTech say 3 COVID shots elicit good response in children under 5

Drugmakers Pfizer Inc and BioNTech SE said on Monday that three doses of their COVID-19 vaccine generated a strong immune response in children under age 5 and was safe and well-tolerated in their clinical trial.

The Independent UK

Pfizer says 3 COVID shots protect children under 5

Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week

Bangkok Post

Omicron infection turbo-charges vaccinated people’s immunity: study

People who are vaccinated and then get infected with Omicron may be primed to overcome a broad range of coronavirus variants, early research suggests.

Benzinga

Where BioNTech Stands With Analysts

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Why BioNTech Stock Is Rising Today

BioNTech SE (NASDAQ: BNTX) shares are trading higher Monday after the company reported financial results and reaffirmed its 2022 outlook.

Benzinga

BioNTech Clocks Over $6B In Q1 Sales, Sticks To FY22 Guidance

BioNTech SE (NASDAQ:BNTX) has reported Q1 FY22 revenues of €6.37 billion compared to €2.05 billion a year ago, mainly due to high demand for the company's COVID-19 vaccine. In Q1 FY22, BioNTech and its partner Pfizer Inc (NYSE:PFE) have invoiced approximately 750 million COVID-19 vaccine doses. As of end-April 2022, the companies have signed orders…

Benzinga

How To Attend BioNTech Q1 2022 Earnings Conference Call

BioNTech (NASDAQ:BNTX) will host a conference call at 08:00 AM ET on May 9, 2022, to discuss Q1 2022 earnings results. How to Attend BioNTech (BNTX) Conference Call Follow this link to access the live webcast.

The Guardian - UK

Pfizer accused of Covid profiteering as first-quarter sales hit $26bn

Pharma firm criticised over pricing and for keeping monopoly control over vaccine and new Paxlovid pill

Benzinga

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis

Here's a roundup of top developments in the biotech space over the last 24 hours.

Salon

Another delay for five-and-under vaccine

The issue isn't around safety, but instead messaging and vaccine effectiveness

Benzinga

What's Happening With BioNTech SE Shares?

Shares of vaccine companies, including BioNTech SE - ADR (NASDAQ: BNTX), are trading higher amid COVID-19 concerns due to rising cases in China.

1 … 5 6 7 8

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Food and Drug Administration

University of Pennsylvania

121 stories

University of Washington

88 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.